<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>8
<FILENAME>form8kitem101ex99may-17.txt
<DESCRIPTION>EXHIBIT 99 PRESS RELEASE
<TEXT>




                                   EXHIBIT 99




<PAGE>


CEL-SCI Corporation


8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
 www.cel-sci.com                                         (703) 506-9460

           CEL-SCI ANNOUNCES $1.51 MILLION REGISTERED DIRECT OFFERING

Vienna,  VA,  Friday,  May 1, 2017 - CEL-SCI  Corporation  (NYSE  MKT:CVM) today
announced  it has entered  into a definitive  agreement  with one  institutional
investor  for an  offering  of shares of common  stock  with gross  proceeds  of
approximately $1.51 million in a registered direct offering.  The closing of the
offering  is  expected  to take  place on or about May 3,  2017,  subject to the
satisfaction of customary closing conditions.

In connection with the offering, the CEL-SCI will issue approximately 13,199,000
registered  shares of common  stock at a  purchase  price of $0.115  per  share.
Concurrently in a private placement, the Company will issue warrants to purchase
up to  9,899,250  shares of its common  stock.  For each  share of common  stock
purchased  in the  registered  direct  offering,  such  investor  in the private
placement will receive from the CEL-SCI an unregistered warrant to purchase 0.75
share of common stock. The warrants have an exercise price of $0.1214 per share,
will be  exercisable  upon the 6 month  anniversary  of the issue date, and will
expire five and a half years from the issue date.

Rodman &  Renshaw,  a unit of H.C.  Wainwright  & Co.,  LLC,  is  acting  as the
exclusive placement agent in connection with the offering.

CEL-SCI  intends  to use the net  proceeds  from the  offering  for the  Phase 3
clinical study and general corporate purposes.

The shares of common stock  described  above (but not the warrants or the shares
of common stock underlying the warrants) are being offered pursuant to a "shelf"
registration statement (File No. 333-205444). Such shares of common stock may be
offered  only by means  of a  prospectus,  including  a  prospectus  supplement,
forming a part of the effective registration statement.

The warrants  described above were offered in a private  placement under Section
4(a)(2) of the Securities Act of 1933, as amended (the "Act"),  and Regulation D
promulgated thereunder and, along with the shares of common stock underlying the
warrants, have not been registered under the Act, or applicable state securities
laws. Accordingly, the warrants and underlying shares of common stock may not be
offered  or  sold  in  the  United  States  except   pursuant  to  an  effective
registration   statement  or  an  applicable  exemption  from  the  registration
requirements of the Act and such applicable state securities laws.

A prospectus supplement and the accompanying prospectus relating to the offering
will be  filed  with the SEC and  will be  available  on the  SEC's  website  at
http://www.sec.gov.  Copies of the  prospectus  supplement,  when filed with the
SEC, and accompanying  prospectus relating to this offering may also be obtained
from H.C. Wainwright & Co., LLC, by emailing  placements@hcwco.com or by calling
646-975-6996.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any of the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,

                                       1
<PAGE>

solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system
to fight cancer and infectious diseases. Its lead investigational immunotherapy,
Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a
pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients
with squamous cell carcinoma of the head and neck. Subject to the partial
clinical hold, the study was designed with the objective that, if the study
endpoint, which is an improvement in overall survival of the subjects treated
with the Multikine treatment regimen plus the current standard of care (SOC) as
compared to subjects treated with the current SOC only, is satisfied, the study
results will be used to support applications that the Company plans to submit to
regulatory agencies in order to seek commercial marketing approvals for
Multikine in major markets around the world. Additional clinical indications for
Multikine that are being investigated include the treatment of cervical
dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in
HIV/HPV co-infected men and women. A Phase 1 trial of the former indication
(treatment of cervical dysplasia in HIV/HPV co-infected women) has been
completed at the University of Maryland. The latter indication (treatment of
peri-anal warts in HIV/HPV co-infected men and women) is being studied in a
Phase 1 trial at the University of California, San Francisco. CEL-SCI has
patents on Multikine from the US, Europe, China, and Japan.

CEL-SCI is also developing its pre-clinical  L.E.A.P.S.  (Ligand Epitope Antigen
Presentation   System)  technology  for  the  potential  treatment  of  pandemic
influenza in hospitalized  patients and as a potential vaccine for the treatment
of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ materially from those projected.  Such statements include, but
are not  limited  to,  statements  about the terms,  expected  proceeds,  use of
proceeds and closing of the offering.  Factors that could cause or contribute to
such  differences  include,  an  inability to  duplicate  the  clinical  results
demonstrated in clinical studies,  timely  development of any potential products
that  can be  shown to be safe and  effective,  receiving  necessary  regulatory
approvals,   difficulties  in  manufacturing  any  of  the  Company's  potential
products,  inability  to raise the  necessary  capital and the risk  factors set
forth from time to time in CEL-SCI's  filings with the  Securities  and Exchange
Commission,  including but not limited to its report on Form 10-K and 10-K/A for
the year ended  September  30, 2016.  The Company  undertakes  no  obligation to
publicly release the result of any revision to these forward-looking  statements
which may be made to reflect the events or  circumstances  after the date hereof
or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has
registered  for  this  investigational  therapy,  and this  proprietary  name is
subject  to FDA  review in  connection  with the  Company's  future  anticipated
regulatory submission for approval.  Multikine has not been licensed or approved
for  sale,  barter  or  exchange  by the  FDA or any  other  regulatory  agency.

                                       2
<PAGE>

Similarly,  its  safety  or  efficacy  has not  been  established  for any  use.
Moreover,  no  definitive   conclusions  can  be  drawn  from  the  early-phase,
clinical-trials  data involving the investigational  therapy Multikine.  Further
research is required,  and early-phase  clinical trial results must be confirmed
in the  Phase 3  clinical  trial  of  this  investigational  therapy  that is in
progress  and that is  currently  subject to a clinical  hold on  enrollment  of
additional new patients.
</TEXT>
</DOCUMENT>
